NT5C and neoplasm: Interestingly, the MuSyC-dose treatment group had the highest average percentage of CD45+ immune cells in the tumor at approximately 12%, significantly higher than R848 and vaccine alone and roughly two times higher than CDN and Max-dose treatment groups (Figure 4E).